Delving into the Latest Updates on HAL Allergy BV with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Immune System Diseases

Respiratory Diseases

Allergen extract

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Allergen extract	1

The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without asthma.
The study has 4 treatment groups: 1 placebo group and 3 groups treated with different doses of HAL-MRE1.

Start Date21 Nov 2018

Sponsor / Collaborator

HAL Allergy BV

EUCTR2009-015012-18-DE / Not yet recruitingNot Applicable

A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. - PURETHAL Grasses Rush study

Start Date09 Feb 2010

Sponsor / Collaborator

HAL Allergy BV

EUCTR2005-005175-16-DE / Not yet recruitingNot Applicable

Twin SUBLIVAC® Grasses Clinical Efficay Study

Start Date20 Jul 2006

Sponsor / Collaborator

HAL Allergy BV

100 Clinical Results associated with HAL Allergy BV

Login to view more data

0 Patents (Medical) associated with HAL Allergy BV

Login to view more data

6

Literatures (Medical) associated with HAL Allergy BV

01 Aug 2023·Journal of Allergy and Clinical Immunology

IgE cross-inhibition between Ara h 1 and Ara h 2 is explained by complex formation of both major peanut allergens

Article

Author: van Ree, Ronald ; Akkerdaas, Jaap H. ; Dreskin, Stephen C. ; Versteeg, Serge A. ; Warmenhoven, Hans J. M. ; Hulsbos, Luuk

Surprisingly, IgE cross-reactivity between the major peanut allergens Ara h 1, 2, and 3 has been reported despite very low sequence identities.We investigated the unexpected cross-reactivity between peanut major allergens.Cross-contamination of purified natural Ara h 1, 2, 3, and 6 was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot test, liquid chromatog.-tandem mass spectrometry (LC-MS/MS), and sandwich ELISA (ELISA).IgE cross-reactivity was studied with sera of peanut-allergic patients (n = 43) by ELISA and ImmunoCAP inhibition using both intact natural and recombinant allergens and synthetic peptides representing postulated Ara h 1 and Ara h 2 cross-reactive epitopes.Both purified nAra h 1 and nAra h 3 were demonstrated to contain small but significant amounts of Ara h 2 and Ara h 6 (<1%) by sandwich ELISA, SDS-PAGE/Western blot anal., and LC-MS/MS.IgE cross-inhibition between both 2S albumins and Ara h 1 and Ara h 3 was only observed when using natural purified allergens, not recombinant allergens or synthetic peptides.Apparent cross-reactivity was lost when purified nAra h 1 was pretreated under reducing conditions, suggesting that Ara h 2 and Ara h 6 contaminations may be covalently bound to Ara h 1 via disulfide interactions.True cross-reactivity of both peanut 2S albumins with Ara h 1 and Ara h 3 could not be demonstrated.Instead, cross-contamination with small quantities was shown to be sufficient to cause significant cross-inhibition that can be misinterpreted as mol. cross-reactivity.Diagnostic tests using purified nAra h 1 and nAra h 3 can overestimate their importance as major allergens as a result of the presence of contaminating 2S albumins, making recombinant Ara h 1 and Ara h 3 a preferred alternative.

01 Feb 2021·Int. Journal of Clinical Pharmacology and TherapeuticsQ4 · MEDICINE

The mode of action of sugammadex on coagulation

Q4 · MEDICINE

Article

Author: Kluft, Cornelis ; de Kam, Pieter-Jan ; Burggraaf, Jacobus ; Moerland, Matthijs ; Kruithof, Annelieke C. ; Laterveer, Ria H.

OBJECTIVETo explore the mode of action (MoA) by which sugammadex interferes with coagulation.MATERIALS AND METHODSThe effect of sugammadex on various steps in the coagulation cascade including thrombin generation, factor Xa activity, and factor Xa generation was explored in human plasma.RESULTSSugammadex did not affect a conventional thrombin generation test (TGT), while it prolongs activated partial thromboplastin time (APTT) and prothrombin time (PT). However, a customized TGT with PT reagent revealed sugammadex effects. In addition, sugammadex prolonged a one-step prothrombinase-induced clotting time (PiCT) using human factor Xa. Furthermore, sugammadex interfered with factor Xa generation induced by an intrinsic and not by an extrinsic activator, nor by Russell's viper venom factor X (RVV-X).CONCLUSIONAdapted, rather than standard, experiments show that sugammadex is likely to decrease factor Xa activity in the common pathway and activation of factor X specifically in the intrinsic pathway.

19 May 2011·New England Journal of MedicineQ1 · MEDICINE

Anaphylaxis from Passive Transfer of Peanut Allergen in a Blood Product

Q1 · MEDICINE

Letter

Author: Elisabeth C.M. van Pampus ; Irma Joosten ; Joseph L. Baumert ; Paul P. Brons ; Stef J. Koppelman ; Joannes F.M. Jacobs

Anaphylactic transfusion reactions from passive transfer of IgE have been documented, but a case is now reported in which the eliciting factor was a food allergen in peanuts ingested by blood donors before donation.

100 Deals associated with HAL Allergy BV

Login to view more data

100 Translational Medicine associated with HAL Allergy BV

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

House dust mite allergy immunotherapy sublingual	Allergic rhinoconjunctivitis More	Approved
HAL-MRE1	Allergic rhinoconjunctivitis More	Pending
Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)	Rhinitis, Allergic More	Pending